|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
A total of 59 PTCs from both groups were evaluated for BRAF mutation on tumor tissue and on ctDNA from plasma samples by real-time polymerase chain reaction (PCR) and digital PCR.
|
29566452 |
2018 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E Gene Mutation Is Associated With Bilateral Malignancy of Papillary Thyroid Cancer.
|
30219154 |
2018 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutations were more common in C-PTC (P = 0.002).
|
30352402 |
2018 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutations occur in about 40-45% of all papillary thyroid carcinomas (PTCs) and of which 99.7% is the BRAFV600E mutation.
|
29209896 |
2018 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
CONCLUSIONS Expression of the BRAF V600E mutation and RET/PTC translocation promoted the activity of NF-κB, expression of inflammatory mediators, and lymph node metastases in patients with PTC.
|
30254191 |
2018 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Expression of SLC5A5, SLC2A4, HK1, and G6PD mRNA was lower in PTC without BRAF mutation.
|
29978611 |
2018 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
The prevalence of BRAF mutation in PTC-TCF and TCVPTC was comparable and both were significantly higher than that in classical PTC.
|
30352403 |
2018 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Risk factors for the occurrence of BRAF mutations in PTC were evaluated using multivariate logistic regression models.
|
28258306 |
2018 |
|
Papillary thyroid carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
The prognostic risk of male sex in PTC can thus be stratified by BRAF status in clinical application.
|
30070937 |
2018 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Antigen retrieval time in 32 min and 64 min showed satisfactory intensity and homogeneity of BRAF V600E staining in CRC and PTC samples, respectively.
|
30009773 |
2018 |
|
Papillary thyroid carcinoma
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
In the present study, reverse transcription-quantitative polymerase chain reaction was used to determine the expression levels of miR-9-5p and BRAF mRNA in patients with papillary thyroid cancer (PTC).
|
30333891 |
2018 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
The aim of the present study was to evaluate the possible diagnostic role of the combined performance of BRAF mutation analysis and MIBI scintigraphy in papillary thyroid cancer (PTC) patients with incomplete bio-chemical response to first radioiodine therapy (RAIT) performed for thyroid remnant ablation.
|
29549631 |
2018 |
|
Papillary thyroid carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
Concurrently, we evaluated the outcomes of combined targeting of the proteasome pathway in addition to selective BRAF inhibitors in cases of PTC.
|
29269566 |
2018 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Our study showed that there was no significant association of BRAF V600E mutation with the gender, age, tumor size and lymph node metastasis in PTCs.
|
29254799 |
2018 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
We studied the expression of PD-L1, PD-1, and BRAF V600E by immunohistochemical staining in 110 cases of PTC with a diameter > 1 cm.
|
29651624 |
2018 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment.
|
29165667 |
2018 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
The B-Raf proto-oncogene serine∕threonine kinase (BRAF) V600E (BRAF(V600E)) mutation represents a very specific marker for papillary thyroid carcinoma (PTC), including microcarcinomas (PTMCs).
|
30534813 |
2018 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E mutation was found in 24 of the 60 (40%) PTC cases, with mean tumor size of 1.59 ± 1.20 cm.
|
30509240 |
2018 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Rare BRAF mutations of codon 599 have been also described in a few patients with papillary thyroid cancer and melanoma.
|
29232305 |
2018 |
|
Papillary thyroid carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
Nine thyroid carcinomas with infarction were characterized as BRAF-like papillary thyroid carcinoma based on molecular driver categorization and histologic diagnosis.
|
29868707 |
2018 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Importantly, its expression was higher in a PTC cell line that harbors BRAF V600E mutation than in a PTC cell line that harbors RET/PTC1.
|
29560564 |
2018 |
|
Papillary thyroid carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
However, the mean TIMP3 protein level was significantly lower in tumoral tissues, compared to matched non-tumoral tissues in BRAF (+) PTC (P=0.003); TIMP3 protein level was significantly lower in tumoral tissues compared to matched non-tumoral tissues in BRAF (+), in subjects who had no lymph node metastasis and also in subjects with lymph node metastasis in both BRAF positive and negative PTC cases.
|
29868127 |
2018 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
In this study, we used the KTC1 cell line as a model for human advanced papillary thyroid cancer (PTC) because the cells harbor the heterozygous BRAF (V600E) mutation together with the C250T TERT promoter mutation.
|
30265861 |
2018 |
|
Papillary thyroid carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
We therefore tested TM for antineoplastic activity in <i>BRAF<sup>V600E</sup></i> -positive PTC.<b>Experimental Design:</b> The efficacy of TM alone and in combination with current standard-of-care lenvatinib and sorafenib or BRAF and MEK1/2 inhibitors vemurafenib and trametinib was examined in <i>BRAF<sup>V600</sup></i><sup>E</sup>-positive human PTC cell lines and a genetically engineered mouse PTC model.<b>Results:</b> TM inhibited MEK1/2 kinase activity and transformed growth of PTC cells.
|
30065097 |
2018 |
|
Papillary thyroid carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
BRAF = B-Raf proto-oncogene, serine/threonine kinase; CI = confidence interval; CT = computed tomography; DTC = differentiated thyroid cancer; FDG = fluorodeoxyglucose; PET = positron emission tomography; PTC = papillary thyroid cancer; SUV = standardized uptake value.
|
29144823 |
2018 |